BioSpace

AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover

In the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with good symptom control.

By BioSpace

1 min read
AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover
AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights